DOWNLOAD

DATA SHEET

Lapimicina® L.A. Subcutanea Oxitetyacilina long-acting Kind Antibiotic Formulation Injectable Presentations Flask with 250 mL Registry REG. SAGARPA Q - 2083 - 051
  • FORMULA
    EACH ML CONTAINS: based Oxytetracycline: 200 mg (as dihydrate) Vehicle qs 1 mL
  • DESCRIPTION
    INDICATIONS: Long acting oxytetracycline, indicated in the treatment of pneumonia, diarrhea, FPD, keratoconjunctivitis, actinobacilosis, leptospirosis, anaplasmosis, mastitis, metritis and agalactea and septicemic infections. SUSCEPTIBLE ORGANISMS: Pasteurella spp., Haemophilus spp., Moraxella bovis, Fusobacterium necrophorum, Escherichia coli, Actinobacillus lignieresi, Leptospira spp., Staphylococcus spp., Streptococcus spp., Actinobacillus pleuropneumoniae.
  • DOSE
    Given by deep intramuscular or subcutaneous injection at 20 mg of oxytetracycline per kg body weight. Equivalent to applying 1 mL of product per 10 kg. Do not apply more than 20 mL per injection site. Interactions and incompatibility with other products: The bacteriostatic drugs may interfere with the bactericidal action of penicillin so it is best to avoid treatment Lapimicina® LA in conjunction with penicillins.
  • USE
    Cattle, pigs, sheep and goats.
  • WARNINGS
    Overdosing may cause retention of antibiotic residues beyond the suspension period. Reactions have occurred anaphylactic or allergic nature, sometimes fatal, in hypersensitive animals following injection of Oxytetracycline. If this occurs, discontinue treatment and consider antihistamines. Use of the product may cause transient local irritation manifested by swelling and discoloration at the injection site. The pain of injection can be minimized by heating the solution to body temperature before administration and avoiding a bad technique injected. After treatment, the animals may have transient hemoglobinuria. Like all antibiotic preparations, use of this product can result in overgrowth of resistant organism, including fungi. The absence of a favorable response after treatment, or developing new signs or symptoms may suggest overgrowth of non-susceptible organisms. If superinfection happens, the use of this product should be discontinued and the treatment should be reconsidered.

All rights reserved Lapisa 2018 © | Notice of Privacy